middle.news
How Aroa Biosurgery’s Myriad Portfolio Drove 14% Sales Growth in H1 FY26
8:41am on Tuesday 25th of November, 2025 AEDT
•
Healthcare
Read Story
How Aroa Biosurgery’s Myriad Portfolio Drove 14% Sales Growth in H1 FY26
8:41am on Tuesday 25th of November, 2025 AEDT
Key Points
Product sales up 14% to NZ$44.6 million, led by 30% growth in Myriad portfolio
Normalised EBITDA profit of NZ$1.8 million versus prior period loss
Reaffirmed FY26 guidance – NZ$92-100 million revenue and NZ$5-8 million EBITDA profit
US Medicare reimbursement changes expected to benefit Symphony product
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE